AngioDynamics Inc. has announced the commencement of the RECOVER-AV clinical trial, marking the enrollment of the first patient. This multi-center, multi-national study aims to evaluate the AlphaVac Multipurpose Mechanical Aspiration $(MMA)$ F1885 System for the treatment of acute, intermediate-risk pulmonary embolism (PE). The trial will involve up to 20 hospital-based sites across Europe, Canada, and Hong Kong. The primary safety endpoint will assess the incidence of adverse events through 12 months, with functional and quality-of-life outcomes evaluated at 30 days and 12 months. Additional investigations, including Cardiac MRI and exercise testing, will contribute to a comprehensive assessment of long-term recovery. Results from the trial are anticipated in the future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。